Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tiss
scientific article published on 04 March 2020
Author/s
author: Lorenzo D'Ambrosio, Jean-Yves Blay, Giovanni Grignani, Anna M Czarnecka, Christine Chevreau, Silvia Stacchiotti, Bernd Kasper, Alessandro Gronchi, Armin Tuchscherer, Hans J. Gelderblom, Axel Le Cesne, Isabelle Ray-Coquard, Florence Duffaud, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Javier Martín-Broto, Roberta Sanfilippo, Bruno Vincenzi, Piotr Rutkowski
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.